Status:
UNKNOWN
The Influence of Inhaled CorticoSteroids Adherence on Treatment Response to Mepolizumab in Severe Eosinophilic Asthma
Lead Sponsor:
University Hospital Birmingham
Conditions:
Asthma; Eosinophilic
Eligibility:
All Genders
18-85 years
Brief Summary
The study aim is to look at the effect of the regular use of inhaled corticosteroids on the response and received from mepolizumab treatment which you are receiving or had received before.
Detailed Description
Examine the outcomes of 250 patients who have been treated with mepolizumab within BRSAS and compare the adherence to ICS in the responders and non-responder groups. If confirmed that non-adherence to...
Eligibility Criteria
Inclusion
- Patients of 18 years of age or higher
- Patients commenced on mepolizumab within the BRSAS network
- Patients who have at least 1 mepolizumab injection and with at least 3 months follow-up data from the time of treatment initiation
- Patients must be able and willing to give informed consent to participate in the study . An Interpreter will be provided for those patients where English is not their first language.
Exclusion
- Refusal or inability to provide informed consent
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05241769
Start Date
March 1 2022
End Date
September 1 2023
Last Update
February 16 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.